Neuvasq Biotechnologies in San Francisco for JPM 2025!
The annual JP Morgan Healthcare Conference is always a key moment for the biotech and Pharma ecosystem. This year, Ralph Laufer, CSO of Neuvasq Biotechnologies, joined Emmanuel Lacroix, CEO, to network with potential new partners and investors.
🔬 What was at the heart of our discussions?
Share preclinical evidence demonstrating the successful engineering of innovative, highly potent Wnt surrogate antibodies, that restore the integrity of the blood-retinal barrier.
🏃♂️ Networking… on the move!
Because the best conversations don’t always happen around a table, we also joined morning runs with friends and other industry leaders – a great way to build relationships in a dynamic and engaging way.
📅 And this is just the beginning!
With so much data to share during upcoming scientific conferences and investors meetings, 2025 is shaping up to be an exciting year!
👉 Follow our LinkedIn page to stay updated on our latest news and upcoming events.
Cookie policy